tradingkey.logo
tradingkey.logo
Suchen

Journey Medical Corp

DERM
Zur Watchlist hinzufügen
7.090USD
+0.050+0.71%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
192.46MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Journey Medical Corp Unternehmen

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.

Journey Medical Corp Informationen

BörsenkürzelDERM
Name des UnternehmensJourney Medical Corp
IPO-datumNov 12, 2021
CEOMaraoui (Claude)
Anzahl der mitarbeiter41
WertpapierartOrdinary Share
GeschäftsjahresendeNov 12
Addresse9237 E Via De Ventura Blvd., Suite 105
StadtSCOTTSDALE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl85258
Telefon14804346670
Websitehttps://journeymedicalcorp.com/
BörsenkürzelDERM
IPO-datumNov 12, 2021
CEOMaraoui (Claude)

Führungskräfte von Journey Medical Corp

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.29M
+10.02%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
470.73K
+32.73%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
330.44K
-14.36%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
187.57K
+46.27%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
81.44K
-21.42%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
81.44K
-21.42%
Mr. Michael C. Pearce
Mr. Michael C. Pearce
Independent Director
Independent Director
10.00K
-471.73%
Ms. Jaclyn Jaffe
Ms. Jaclyn Jaffe
Investor Relations
Investor Relations
--
--
Mr. Justin Smith
Mr. Justin Smith
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.29M
+10.02%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
470.73K
+32.73%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
330.44K
-14.36%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
187.57K
+46.27%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
81.44K
-21.42%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
81.44K
-21.42%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Journey Medical Corp?

Die fünf größten Anteilseigner von Journey Medical Corp sind: Mr. Claude Maraoui

Wie viele Institutionen halten Anteile an Journey Medical Corp (DERM)?

Mit Stand vom 2026Q1 halten 137 Institutionen Anteile an Journey Medical Corp, mit einem Gesamtmarktwert von etwa 12.08M, was 56.62% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 2740272.00 gestiegen.

Was ist die größte Einnahmequelle von Journey Medical Corp?

Am 2026Q1 erzielte das Geschäft mit Qbrexa für Journey Medical Corp den höchsten Umsatz in Höhe von 25.01M, was 40.85% des Gesamtumsatzes entspricht.